Intelligent Bio Solutions updates FDA 510(k) timeline; clearance expected H2 2026

INTELLIGENT BIO SOLUTIONS INC.

Will commence clinical studies before year-end to gather additional data for FDA 510(k) resubmission for codeine fingerprint test.
Anticipates FDA 510(k) clearance for opiate codeine use in the second half of 2026.
Drug screening system adopted by over 450 accounts in 24 countries with 18 distribution partners.
Currently marketed outside U.S. and for forensic use only; FDA clearance would open broader U.S. commercial entry.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.